Feedback / Questions
ifinatamab deruxtecan (DS-7300) - Daiichi Sankyo, Merck (MSD)
ifinatamab deruxtecan: Data from P2 IDeate-Lung01 trial (NCT05280470) extensive stage SCLC in H1 FY2025
(Daiichi Sankyo)
-
May 7, 2025 -
FY2024 Results
P2 data
•
Lung Cancer • Oncology • Small Cell Lung Cancer
https://www.daiichisankyo.com/files/investors/library/quarterly_result/2024/4Q/FY2024Q4_Financial_Results_Presentation_E.pdf
May 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious